Aldeyra Therapeutics (NASDAQ:ALDX) Stock Rating Lowered by StockNews.com

Aldeyra Therapeutics (NASDAQ:ALDX) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Several other equities research analysts have also issued reports on ALDX. Oppenheimer reissued an “outperform” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Monday.

Aldeyra Therapeutics Stock Up 1.2 %

NASDAQ ALDX opened at $4.17 on Monday. The stock has a market cap of $247.74 million, a PE ratio of -8.18 and a beta of 1.45. Aldeyra Therapeutics has a fifty-two week low of $1.42 and a fifty-two week high of $11.97. The business has a 50 day moving average price of $3.72 and a two-hundred day moving average price of $3.23.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.13. Sell-side analysts anticipate that Aldeyra Therapeutics will post -0.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other Aldeyra Therapeutics news, insider Bruce Greenberg sold 13,201 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.41, for a total value of $45,015.41. Following the sale, the insider now directly owns 120,699 shares of the company’s stock, valued at $411,583.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Bruce Greenberg sold 13,201 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.41, for a total value of $45,015.41. Following the completion of the transaction, the insider now owns 120,699 shares of the company’s stock, valued at $411,583.59. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Todd C. Brady sold 97,914 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $3.27, for a total value of $320,178.78. Following the transaction, the chief executive officer now directly owns 1,556,622 shares of the company’s stock, valued at approximately $5,090,153.94. The disclosure for this sale can be found here. Insiders have purchased 355,933 shares of company stock valued at $1,473,245 over the last three months. Company insiders own 7.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its stake in Aldeyra Therapeutics by 23.4% during the first quarter. BNP Paribas Financial Markets now owns 25,278 shares of the biotechnology company’s stock valued at $83,000 after buying an additional 4,797 shares in the last quarter. Deutsche Bank AG boosted its stake in Aldeyra Therapeutics by 2.2% during the third quarter. Deutsche Bank AG now owns 294,775 shares of the biotechnology company’s stock valued at $1,969,000 after buying an additional 6,470 shares in the last quarter. Prime Capital Investment Advisors LLC bought a new position in Aldeyra Therapeutics during the fourth quarter valued at about $35,000. SG Americas Securities LLC bought a new position in Aldeyra Therapeutics during the fourth quarter valued at about $39,000. Finally, Barclays PLC boosted its stake in Aldeyra Therapeutics by 9.0% during the third quarter. Barclays PLC now owns 138,311 shares of the biotechnology company’s stock valued at $924,000 after buying an additional 11,447 shares in the last quarter. Institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.